Compare TG Therapeutics Inc (TGTX) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard International High Dividend Yield ETF — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Vanguard International High Dividend Yield ETF trades at $105.38. Which is the better fit depends on your goals.
| TGTX | VYMI | |
|---|---|---|
Market Cap | $8.53B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $107.13 |
52-Week Low | $26.94 | $82.92 |
Enterprise Value | $8.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
VYMI trades at $106.20, down 0.78% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF has gained attention for its international high-dividend yield strategy, recently hitting a 52-week high near current levels. Recent news highlights its outperformance versus domestic dividend ETFs and growing institutional interest.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's strong dividend growth. Key risks include currency fluctuations and global economic volatility. With technical support at $105-106 and resistance at $107-108, the ETF offers income-focused exposure to international equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
